Your browser doesn't support javascript.
loading
Efficacy of a Chinese herbal formula on hepatitis B e antigen-positive chronic hepatitis B patients.
Xing, Yu-Feng; Wei, Chun-Shan; Zhou, Tian-Ran; Huang, Dan-Ping; Zhong, Wei-Chao; Chen, Bin; Jin, Hua; Hu, Xiao-Yu; Yang, Zhi-Yun; He, Qing; Jiang, Kai-Ping; Jiang, Jun-Min; Hu, Zhen-Bin; Deng, Xin; Yang, Fan; Li, Feng-Yi; Zhao, Gang; Wang, Li-Chun; Mi, Yu-Qiang; Gong, Zuo-Jiong; Guo, Peng; Wu, Jian-Hua; Shi, Wei-Qun; Yang, Hong-Zhi; Zhou, Da-Qiao; Tong, Guang-Dong.
Afiliación
  • Xing YF; Department of Hepatology, Shenzhen Traditional Chinese Medicine Hospital, The Fourth Clinical Medical College of Guangzhou University of Chinese Medicine, Shenzhen 518033, Guangdong Province, China.
  • Wei CS; Department of Hepatology, Shenzhen Traditional Chinese Medicine Hospital, The Fourth Clinical Medical College of Guangzhou University of Chinese Medicine, Shenzhen 518033, Guangdong Province, China.
  • Zhou TR; Department of Hepatology, Shenzhen Traditional Chinese Medicine Hospital, The Fourth Clinical Medical College of Guangzhou University of Chinese Medicine, Shenzhen 518033, Guangdong Province, China.
  • Huang DP; Department of Hepatology, Shenzhen Traditional Chinese Medicine Hospital, The Fourth Clinical Medical College of Guangzhou University of Chinese Medicine, Shenzhen 518033, Guangdong Province, China.
  • Zhong WC; Department of Hepatology, Shenzhen Traditional Chinese Medicine Hospital, The Fourth Clinical Medical College of Guangzhou University of Chinese Medicine, Shenzhen 518033, Guangdong Province, China.
  • Chen B; Department of Hepatology, The First Hospital of Hunan University of Chinese Medicine, Changsha 410007, Hunan Province, China.
  • Jin H; Department of Integrated Traditional and Western Medicine on Liver Diseases, Beijing Youan Hospital, Capital Medical University, Beijing 100069, China.
  • Hu XY; Department of Infectious Disease, The Affiliated Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu 610032, Sichuan Province, China.
  • Yang ZY; Department of Integrated Traditional and Western Medicine on Liver Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China.
  • He Q; The First Department of Hepatology, Shenzhen No. 3 People's Hospital, Shenzhen 518100, Guangdong Province, China.
  • Jiang KP; Department of Hepatology, Foshan Hospital of Traditional Chinese Medicine, Foshan 528000, Guangdong Province, China.
  • Jiang JM; Department of Hepatology, Guangdong Hospital of Traditional Chinese Medicine, Guangzhou 510006, Guangdong Province, China.
  • Hu ZB; Department of Hepatology, The First Affiliated Hospital of Guangxi University of Chinese Medicine, Nanning 530012, Guangxi Province, China.
  • Deng X; Department of Hepatology, Ruikang Hospital, Guangxi University of Chinese Medicine, Nanning 530012, Guangxi Province, China.
  • Yang F; Hubei Provincial Hospital of Traditional Chinese Medicine, Wuhan 430060, Hubei Province, China.
  • Li FY; Treatment and Research Center of Infectious Disease, 302 Military Hospital of China, Beijing 100039, China.
  • Zhao G; Department of Hepatology, Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 201204, China.
  • Wang LC; Center of Infectious Disease, Huaxi Hospital, Sichuan University, Chengdu 610044, Sichuan Province, China.
  • Mi YQ; Department of Infectious Disease, Tianjin Infectious Disease Hospital, Tianjin 300192, China.
  • Gong ZJ; Department of Infectious Disease, Hubei People's Hospital, Wuhan 430060, Hubei Province, China.
  • Guo P; Department of Hepatology, Xiyuan Hospital, China Academy of Chinese Medical Science, Beijing 100080, China.
  • Wu JH; Center of Hepatology, Xiamen Hospital of Traditional Chinese Medicine, Xiamen 361009, Fujian Province, China.
  • Shi WQ; Department of Hepatology, Xinhua Hospital, Zhejiang University of Traditional Chinese Medicine, Hangzhou 310005, Zhejiang Province, China.
  • Yang HZ; Department of Traditional Chinese Medicine, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510620, Guangdong Province, China.
  • Zhou DQ; Department of Hepatology, Shenzhen Traditional Chinese Medicine Hospital, The Fourth Clinical Medical College of Guangzhou University of Chinese Medicine, Shenzhen 518033, Guangdong Province, China.
  • Tong GD; Department of Hepatology, Shenzhen Traditional Chinese Medicine Hospital, The Fourth Clinical Medical College of Guangzhou University of Chinese Medicine, Shenzhen 518033, Guangdong Province, China. tgd755@163.com.
World J Gastroenterol ; 26(30): 4501-4522, 2020 Aug 14.
Article en En | MEDLINE | ID: mdl-32874061
BACKGROUND: No guideline recommends antiviral therapy for hepatitis B e antigen (HBeAg)-positive chronic hepatitis B patients with persistently normal alanine aminotransferase levels and a high hepatitis B virus (HBV) DNA viral load. AIM: To evaluate the feasibility and safety of a Chinese herbal formula as a therapeutic option for chronic HBV infection. METHODS: In total, 395 patients (30-65 years old) with confirmed HBeAg-positive chronic hepatitis B infection and persistently normal alanine aminotransferase were randomized to receive either Chinese herbal formula or placebo for 96 wk. Endpoints to evaluate therapeutic efficacy included: (1) HBV DNA levels decreased to less than 4 log10 IU/mL at weeks 48 and 96; and (2) HBeAg clearance and seroconversion rates at weeks 48 and 96. RESULTS: HBV DNA levels ≤ 4 log10 IU/mL were 10.05% at week 48 and 18.59% at week 96 in the treatment group. The HBeAg clearance and conversion rates were 8.54% and 8.04% at week 48 and 16.08% and 14.57% at week 96, respectively. However, HBV DNA levels ≤ 4 log10 IU/mL were 2.55% and 2.55% at weeks 48 and 96, respectively, and the HBeAg clearance rates were 3.06% and 5.61% at weeks 48 and 96, respectively, in the control group. The quantitative hepatitis B surface antigen and HBeAg levels at baseline and changes during the treatment period as well as the alanine aminotransferase elevation at weeks 12 and 24 were strong predictors of HBeAg clearance. CONCLUSION: High rates of HBV DNA reduction, HBeAg clearance and seroconversion could be achieved with Chinese herbal formula treatments, and the treatments were relatively safe for HBeAg-positive chronic hepatitis B-infected patients with persistently normal alanine aminotransferase. The ability of the compound to modulate host immune function probably contributed to this effect.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Hepatitis B Crónica / Antígenos e de la Hepatitis B Tipo de estudio: Clinical_trials / Diagnostic_studies / Guideline / Prognostic_studies Límite: Adult / Aged / Humans / Middle aged País/Región como asunto: Asia Idioma: En Revista: World J Gastroenterol Asunto de la revista: GASTROENTEROLOGIA Año: 2020 Tipo del documento: Article País de afiliación: China Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Hepatitis B Crónica / Antígenos e de la Hepatitis B Tipo de estudio: Clinical_trials / Diagnostic_studies / Guideline / Prognostic_studies Límite: Adult / Aged / Humans / Middle aged País/Región como asunto: Asia Idioma: En Revista: World J Gastroenterol Asunto de la revista: GASTROENTEROLOGIA Año: 2020 Tipo del documento: Article País de afiliación: China Pais de publicación: Estados Unidos